Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 14/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17470193 | 0.92 | FGFR3 (0.69) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070239 | 0.91 | FGFR3 (0.51) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17470097 | 0.91 | POLB (0.50) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070236 | 0.89 | FGFR3 (0.58) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17469966 | 0.87 | LRRK2 (0.47) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17469957 | 0.85 | FGFR3 (0.54) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070247 | 0.84 | FGFR3 (0.47) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070489 | 0.84 | LRRK2 (0.42) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17469965 | 0.84 | POLB (0.49) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17470086 | 0.83 | FGFR3 (0.60) | FGFR3KCNH2FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | FGFR3 1/4885KCNH2 2621/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.